J. Timothy Greenamyre, MD, PhD

Love Family Professor of Neurology


  • Vice Chair, Neurology
  • Director, Pittsburgh Institute for Neurodegenerative Diseases (PIND)

Biographical Sketch

Dr. Greenamyre obtained his MD and PhD (Neuroscience) degrees from the University of Michigan. He is a Movement Disorders expert, recognized as one of the Best Doctors in America, and an internationally recognized researcher into the causes and novel treatments of neurodegenerative diseases. He is Chief of the clinical Movement Disorders Division and Director of the Pittsburgh Institute for Neurodegenerative Diseases.

Education & Training

  • PhD, University of Michigan, Neuroscience
  • MD, University of Michigan

Specialized Areas of Clinical, Research and/or Educational Interests

  • Research: Laboratory investigation of Parkinson’s disease pathogenesis; Gene-environment interactions in Parkinson’s disease causation
  • Clinical: Care of Movement Disorders

Board Certifications

  • American Board of Psychiatry and Neurology

Professional Organization Membership

  • Association of American Physicians
  • American Academy of Neurology
  • American Neurological Association
  • Movement Disorders Society

Honors & Awards

  • Listed, Best Doctors in America
  • Reviewing Editor, Science Translational Medicine
  • Chair, Gordon Research Conference on Parkinson’s Disease
  • Faculty member, F1000Prime (Neuropharmacology & Psychopharmacology Section)
  • Jacob Hooisma Keynote Lecture, Joint Meeting of the Neurotoxicity Society and the

Selected Recent Publications

Schapira AH, Olanow CW, Greenamyre JT, Bezard E. Slowing of neurodegeneration in Parkinson's disease and Huntington's disease: future therapeutic perspectives. Lancet. 2014 Aug 9;384(9942):545-55. doi: 10.1016/S0140-6736(14)61010-2. Epub 2014 Jun 18. PMID: 24954676.

Zharikov AD, Cannon JR, Tapias V, Bai Q, Horowitz MP, Shah V, El Ayadi A, Hastings TG, Greenamyre JT, Burton EA. shRNA targeting α-synuclein prevents neurodegeneration in a Parkinson's disease model. J Clin Invest. 2015 Jul 1;125(7):2721-35. doi: 10.1172/JCI64502. Epub 2015 Jun 15. PMID: 26075822; PMCID: PMC4563670.

Di Maio R, Barrett PJ, Hoffman EK, Barrett CW, Zharikov A, Borah A, Hu X, McCoy J, Chu CT, Burton EA, Hastings TG, Greenamyre JT. α-Synuclein binds to TOM20 and inhibits mitochondrial protein import in Parkinson's disease. Sci Transl Med. 2016 Jun 8;8(342):342ra78. doi: 10.1126/scitranslmed.aaf3634. PMID: 27280685; PMCID: PMC5016095.

Di Maio R, Hoffman EK, Rocha EM, Keeney MT, Sanders LH, De Miranda BR, Zharikov A, Van Laar A, Stepan AF, Lanz TA, Kofler JK, Burton EA, Alessi DR, Hastings TG, Greenamyre JT. LRRK2 activation in idiopathic Parkinson's disease. Sci Transl Med. 2018 Jul 25;10(451):eaar5429. doi: 10.1126/scitranslmed.aar5429. PMID: 30045977; PMCID: PMC6344941.

Rocha EM, De Miranda BR, Castro S, Drolet R, Hatcher NG, Yao L, Smith SM, Keeney MT, Di Maio R, Kofler J, Hastings TG, Greenamyre JT. LRRK2 inhibition prevents endolysosomal deficits seen in human Parkinson's disease. Neurobiol Dis. 2020 Feb;134:104626. doi: 10.1016/j.nbd.2019.104626. Epub 2019 Oct 13. PMID: 31618685; PMCID: PMC7345850.